<DOC>
	<DOCNO>NCT01250379</DOCNO>
	<brief_summary>This randomize , open-label , parallel-group study ass efficacy afety Avastin ( bevacizumab ) combination chemotherapy versus chemother apy alone second- third-line therapy patient locally recurrent r metastatic breast cancer progress first-line therapy Avastin chemotherapy . Patients randomize receive either Avastin ( 15 mg/kg e 3 week 10 mg/kg every 2 week intravenously ) plus standard chemotherapy chemotherapy alone . Anticipated time study treatment third-line disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Chemotherapy Patients With Breast Cancer Progressing After First-Line Therapy With Avastin Chemotherapy ( TANIA )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Female patient , &gt; /= 18 year age Histologically confirm HER2negative breast cancer Disease progression follow firstline treatment Avastin chemotherapy locally recurrent metastatic breast cancer Avastin treatment firstline set must minimum 4 cycle ( 15 mg/kg ) 6 cycle ( 10 mg/kg ) combination chemotherapy ECOG performance status 02 At least 28 day since prior radiation therapy surgery recovery treatment Antiangiogenic therapy antivascular endothelial growth factor Avastin firstline treatment Active malignancy superficial basal cell superficial squamous cell carcinoma skin , situ carcinoma cervix breast within last 5 year Inadequate renal function Clinically relevant cardiovascular disease Known CNS disease except treated brain metastasis Chronic daily treatment highdose aspirin ( &gt; 325 mg/day ) clopidogrel ( &gt; 75 mg/day ) Pregnant lactate woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>